Gallbladder Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Biliary Tract Cancer (390)

Cholangiocarcinoma (219)

Biliary Tract Cancer (390)

Cholangiocarcinoma (219)

›

No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
MSI-H/dMMR	Gallbladder Cancer	MSI-H/dMMR	Gallbladder Cancer	dostarlimab-gxly Resistant: C1 - Off-label dostarlimab-gxly Resistant : C1	dostarlimab-gxly Resistant: C1 - Off-label dostarlimab-gxly Resistant : C1
HER-2 overexpression	Gallbladder Cancer	HER-2 overexpression	Gallbladder Cancer	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1
MSI-H/dMMR	Gallbladder Cancer	MSI-H/dMMR	Gallbladder Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
BRCA1 mutation	Gallbladder Cancer	BRCA1 mutation	Gallbladder Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
TMB-H	Gallbladder Cancer	TMB-H	Gallbladder Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
MET amplification	Gallbladder Cancer	MET amplification	Gallbladder Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ERBB3 mutation	Gallbladder Cancer	ERBB3 mutation	Gallbladder Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3
HER-2 amplification	Gallbladder Cancer	HER-2 amplification	Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
HER-2 amplification	Gallbladder Cancer	HER-2 amplification	Gallbladder Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3
HER-2 amplification	Gallbladder Cancer	HER-2 amplification	Gallbladder Cancer	trastuzumab + lapatinib Sensitive: C3 – Early Trials trastuzumab + lapatinib Sensitive : C3	trastuzumab + lapatinib Sensitive: C3 – Early Trials trastuzumab + lapatinib Sensitive : C3
ERBB3 mutation	Gallbladder Cancer	ERBB3 mutation	Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
ERBB3 amplification	Gallbladder Cancer	ERBB3 amplification	Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
ERBB3 amplification + ERBB3 mutation	Gallbladder Cancer	ERBB3 amplification + ERBB3 mutation	Gallbladder Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
FGFR3-TACC3 fusion	Gallbladder Cancer	FGFR3-TACC3 fusion	Gallbladder Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
BRAF L485W	Gallbladder Cancer	BRAF L485W	Gallbladder Cancer	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
CDKN2A mutation	Gallbladder Cancer	CDKN2A mutation	Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A deletion	Gallbladder Cancer	CDKN2A deletion	Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
DCK positive	Gallbladder Cancer	DCK positive	Gallbladder Cancer	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3
BRAF D594N	Gallbladder Cancer	BRAF D594N	Gallbladder Cancer	binimetinib + encorafenib Sensitive: C3 – Early Trials binimetinib + encorafenib Sensitive : C3	binimetinib + encorafenib Sensitive: C3 – Early Trials binimetinib + encorafenib Sensitive : C3
FGFR mutation	Gallbladder Cancer	FGFR mutation	Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Gallbladder Cancer	FGFR fusion	Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3

Gallbladder Cancer

Associations(45)

Associations
(45)